Effect of β blockers on mortality after myocardial infarction in adults with COPD: Population based cohort study of UK electronic healthcare records

BMJ (Online)

Volumn 347, Issue , 2013, Pages

  Quint, J K ^a   Herrett, E ^a   Bhaskaran, K ^a   Timmis, A ^b   Hemingway, H ^c   Wedzicha, J A ^c   Smeeth, L ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b LONDON CHEST HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; NEBIVOLOL; PROPRANOLOL; SOTALOL;

ADULT; AGE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; DISEASE ASSOCIATION; DISEASE REGISTRY; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; ELECTRONIC MEDICAL RECORD; FACTORIAL ANALYSIS; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; SEX; SMOKING; SURVIVAL; UNITED KINGDOM; AGED; COMPLICATION; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; FEMALE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; REGISTER; TREATMENT OUTCOME; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE-FREE SURVIVAL; ELECTRONIC HEALTH RECORDS; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTRIES; TREATMENT OUTCOME;

EID: 84888193925     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f6650     Document Type: Article

References (34)

1. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010;65:956-62.
2. Wakabayashi K, Gonzalez MA, Delhaye C, Ben-Dor I, Maluenda G, Collins SD, et al. Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction. Am J Cardiol 2010;106:305-9.
3. Bursi F, Vassallo R, Weston SA, Killian JM, Roger VL. Chronic obstructive pulmonary disease after myocardial infarction in the community. Am Heart J 2010;160:95-101.
4. Salisbury AC. Reid KJ. Spertus JA. Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. Am J Cardiol 2007;99:636-41.
5. Kjoller E, Kober L, Iversen K, Torp-Pedersen C. Trace Study Group. Importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction. Eur J Heart Failure 2004;6:71-7.
6. Huiart L, Ernst P, Ranouil X, Suissa S. Oral corticosteroid use and the risk of acute myocardial infarction in chronic obstructive pulmonary disease. Can Respir J 2006;13:134-8.
7. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. (GOLD) 2006, updated 2010. www.goldcopd.org.
8. Anthonisen NR, Connett JE, Murray RP. Smoking and Lung Function of Lung Health Study Participants after 11 years. Am J Respir Crit Care Med 2002;166:675-9.
9. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006;28:1245-57.
10. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al, for the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
11. Schneider C, Bothner U, Jick SS, Meier CR. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010;25:253-60.
12. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.
13. National Collaborating Centre for Primary Care, 2007. Post myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction. www.nice.org.uk/CG048.
14. Olenchock BA, Fonarow GG, Pan W, Hernandez A, Cannon CP; Get With The Guidelines Steering Committee. Current use of β blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol 2009;103:295-300.
15. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of β-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001;37:1950-6.
16. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008;63:301-5.
17. Short PM, Lipworth SI, Elder D, Schembri S, Lipworth BJ. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011;342:d2549.
18. National Clinical Guidelines Centre, 2010. Chronic heart failure: national clinical guideline for diagnosis and management in primary care. August 2010. www.nice.org.uk/nicemedia/live/13099/50514/50514.pdf.
19. Stefan MS, Bannuru RR, Lessard D, Gore JM, Lindenauer PK, Goldberg RJ. The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction: a 10-year retrospective observational study. Chest 2012;141:1441-8.
20. Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis 2007;2:535-40.
21. Herrett E, Smeeth L, Walker L, Weston C; MINAP Academic Group. The myocardial ischaemia national audit project (MINAP). Heart 2010;96:1264-7.
22. Hypertension. Clinical management of primary hypertension in adults. NICE Guideline 34, updated August 2011. www.nice.org.uk/nicemedia/live/13561/56008/ 56008.pdf.
23. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010;137:1091-7.
24. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al, for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
25. Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006;59:437-47.
26. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;4:CD003566.
27. Can beta-blockers be used for people with COPD? Drug Ther Bull 2011;49: 2-5.
28. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010 24;170:880-7.
29. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
30. Niewoehner DE, Lokhnygina Y, Rice K, Kuschner WG, Sharafkhaneh A, Sarosi GA, Krumpe P, Pieper K, Kesten S. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007;131:20-8.
31. Bursi F, Vassallo R, Weston SA, Killian JM, Roger VL. Chronic obstructive pulmonary disease after myocardial infarction in the community. Am Heart J 2010;160:95-101.
32. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003;168:49-53.
33. Parkinson JP, Davis S, Van Staa T. The General Practice Research Database: now and the future. In: Mann R, Andrews EB, eds. Pharmacovigilance. John Wiley, 2007:341-8.
34. Quint JK, Herrett E, Timmis A, Hemingway H, Smeeth L. Survival after the first myocardial infarction is shorter in patients with COPD compared to the general population. Thorax 2011:66(suppl 4):A45-46.